Aubin Moutal1, Wennan Li1, Yue Wang1, Weina Ju2,3, Shizhen Luo1, Song Cai1, Liberty François-Moutal1, Samantha Perez-Miller1, Jackie Hu1, Erik T Dustrude1, Todd W Vanderah1, Vijay Gokhale4, May Khanna1, Rajesh Khanna1,5. 1. Department of Pharmacology, University of Arizona, Tucson, AZ, USA. 2. Department of Neurology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin Province, China. 3. Department of Pharmacology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin Province, China. 4. Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA. 5. Neuroscience Graduate Interdisciplinary Program, College of Medicine, University of Arizona, Tucson, AZ, USA.
Abstract
BACKGROUND AND PURPOSE: N-type voltage-gated calcium (Cav 2.2) channels are critical determinants of increased neuronal excitability and neurotransmission accompanying persistent neuropathic pain. Although Cav 2.2 channel antagonists are recommended as first-line treatment for neuropathic pain, calcium-current blocking gabapentinoids inadequately alleviate chronic pain symptoms and often exhibit numerous side effects. Collapsin response mediator protein 2 (CRMP2) targets Cav 2.2 channels to the sensory neuron membrane and allosterically modulates their function. A 15-amino-acid peptide (CBD3), derived from CRMP2, disrupts the functional protein-protein interaction between CRMP2 and Cav 2.2 channels to inhibit calcium influx, transmitter release and acute, inflammatory and neuropathic pain. Here, we have mapped the minimal domain of CBD3 necessary for its antinociceptive potential. EXPERIMENTAL APPROACH: Truncated as well as homology-guided mutant versions of CBD3 were generated and assessed using depolarization-evoked calcium influx in rat dorsal root ganglion neurons, binding between CRMP2 and Cav 2.2 channels, whole-cell voltage clamp electrophysiology and behavioural effects in two models of experimental pain: post-surgical pain and HIV-induced sensory neuropathy induced by the viral glycoprotein 120. KEY RESULTS: The first six amino acids within CBD3 accounted for all in vitro activity and antinociception. Spinal administration of a prototypical peptide (TAT-CBD3-L5M) reversed pain behaviours. Homology-guided mutational analyses of these six amino acids identified at least two residues, Ala1 and Arg4, as being critical for antinociception in two pain models. CONCLUSIONS AND IMPLICATIONS: These results identify an antinociceptive scaffold core in CBD3 that can be used for development of low MW mimetics of CBD3. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.
BACKGROUND AND PURPOSE: N-type voltage-gated calcium (Cav 2.2) channels are critical determinants of increased neuronal excitability and neurotransmission accompanying persistent neuropathic pain. Although Cav 2.2 channel antagonists are recommended as first-line treatment for neuropathic pain, calcium-current blocking gabapentinoids inadequately alleviate chronic pain symptoms and often exhibit numerous side effects. Collapsin response mediator protein 2 (CRMP2) targets Cav 2.2 channels to the sensory neuron membrane and allosterically modulates their function. A 15-amino-acid peptide (CBD3), derived from CRMP2, disrupts the functional protein-protein interaction between CRMP2 and Cav 2.2 channels to inhibit calcium influx, transmitter release and acute, inflammatory and neuropathic pain. Here, we have mapped the minimal domain of CBD3 necessary for its antinociceptive potential. EXPERIMENTAL APPROACH: Truncated as well as homology-guided mutant versions of CBD3 were generated and assessed using depolarization-evoked calcium influx in rat dorsal root ganglion neurons, binding between CRMP2 and Cav 2.2 channels, whole-cell voltage clamp electrophysiology and behavioural effects in two models of experimental pain: post-surgical pain and HIV-induced sensory neuropathy induced by the viral glycoprotein 120. KEY RESULTS: The first six amino acids within CBD3 accounted for all in vitro activity and antinociception. Spinal administration of a prototypical peptide (TAT-CBD3-L5M) reversed pain behaviours. Homology-guided mutational analyses of these six amino acids identified at least two residues, Ala1 and Arg4, as being critical for antinociception in two pain models. CONCLUSIONS AND IMPLICATIONS: These results identify an antinociceptive scaffold core in CBD3 that can be used for development of low MW mimetics of CBD3. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.
Authors: Su-Bo Yuan; Yuqiang Shi; Jinghong Chen; Xiangfu Zhou; Guangyu Li; Benjamin B Gelman; Joshua G Lisinicchia; Susan M Carlton; Monique R Ferguson; Alai Tan; Sushil K Sarna; Shao-Jun Tang Journal: Ann Neurol Date: 2014-05-28 Impact factor: 10.422
Authors: Klio Maratou; Victoria C J Wallace; Fauzia S Hasnie; Kenji Okuse; Ramine Hosseini; Nipurna Jina; Julie Blackbeard; Timothy Pheby; Christine Orengo; Anthony H Dickenson; Stephen B McMahon; Andrew S C Rice Journal: Eur J Pain Date: 2008-07-07 Impact factor: 3.931
Authors: Stephen Ph Alexander; William A Catterall; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: William C Buchta; Aubin Moutal; Bethany Hines; Constanza Garcia-Keller; Alexander C W Smith; Peter Kalivas; Rajesh Khanna; Arthur C Riegel Journal: Mol Neurobiol Date: 2019-07-29 Impact factor: 5.590
Authors: Aubin Moutal; Yue Wang; Xiaofang Yang; Yingshi Ji; Shizhen Luo; Angie Dorame; Shreya S Bellampalli; Lindsey A Chew; Song Cai; Erik T Dustrude; James E Keener; Michael T Marty; Todd W Vanderah; Rajesh Khanna Journal: Pain Date: 2017-11 Impact factor: 6.961
Authors: Aubin Moutal; Xiaofang Yang; Wennan Li; Kerry B Gilbraith; Shizhen Luo; Song Cai; Liberty François-Moutal; Lindsey A Chew; Seul Ki Yeon; Shreya S Bellampalli; Chaoling Qu; Jennifer Y Xie; Mohab M Ibrahim; May Khanna; Ki Duk Park; Frank Porreca; Rajesh Khanna Journal: Pain Date: 2017-12 Impact factor: 7.926
Authors: Rajesh Khanna; Aubin Moutal; Katherine A White; Aude Chefdeville; Pedro Negrao de Assis; Song Cai; Vicki J Swier; Shreya S Bellampalli; Marissa D Giunta; Benjamin W Darbro; Dawn E Quelle; Jessica C Sieren; Margaret R Wallace; Christopher S Rogers; David K Meyerholz; Jill M Weimer Journal: Pain Date: 2019-11 Impact factor: 7.926
Authors: Rajesh Khanna; Jie Yu; Xiaofang Yang; Aubin Moutal; Aude Chefdeville; Vijay Gokhale; Zunaira Shuja; Lindsey A Chew; Shreya S Bellampalli; Shizhen Luo; Liberty François-Moutal; Maria J Serafini; Taehwan Ha; Samantha Perez-Miller; Ki Duk Park; Amol M Patwardhan; John M Streicher; Henry M Colecraft; May Khanna Journal: Pain Date: 2019-07 Impact factor: 7.926
Authors: Shreya S Bellampalli; Yingshi Ji; Aubin Moutal; Song Cai; E M Kithsiri Wijeratne; Maria A Gandini; Jie Yu; Aude Chefdeville; Angie Dorame; Lindsey A Chew; Cynthia L Madura; Shizhen Luo; Gabriella Molnar; May Khanna; John M Streicher; Gerald W Zamponi; A A Leslie Gunatilaka; Rajesh Khanna Journal: Pain Date: 2019-01 Impact factor: 7.926